Fresenius Medical Care AG

Fresenius Medical Care AG(FMS)股票分析

$22.680

+0.458 (+2.02%)收盘时

Loading chart…
最高
22.730
开盘
22.420
成交量加权均价
22.56
成交量
733.46K
市值
11.25B
最低
22.270
成交额
16.55M
企业价值/息税折旧摊销前利润(TTM)
5.73

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

AI 分析 of Fresenius Medical Care AG (FMS)

持有

Fresenius Medical Care AG is currently trading at $22.17, with a forward P/E of 8.58, indicating it is undervalued compared to its earnings potential. However, the stock has seen a 5.27% increase over the last five days, suggesting some positive momentum. The main risk is its declining U.S. same-market treatment growth, which is down 0.9%, indicating potential challenges ahead.

估值指标

Fresenius Medical Care AG(FMS)当前预期市盈率为 8.58,5 年平均预期市盈率为 12.79。

预期市盈率

低估
5 年均值 P/E
12.79
当前P/E
8.58
高估
16.42
低估
9.16

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
7.17
当前EV/EBITDA
5.73
高估
8.12
低估
6.23

预期市销率

合理
5 年均值 P/S
0.63
当前P/S
0.57
高估
0.75
低估
0.51

持有 FMS 的大户

F

Fresenius SE & Co. KGaA

+ 持有FMS

-8.81%

3个月收益率

FMS 常见问题 —— 由 Alphio AI 解答

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.

Fresenius Medical Care AG is currently trading at $22.17, with a forward P/E of 8.58, indicating it is undervalued compared to its earnings potential. However, the stock has seen a 5.27% increase over the last five days, suggesting some positive momentum. The main risk is its declining U.S. same-market treatment growth, which is down 0.9%, indicating potential challenges ahead.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易